OSE Immunotherapeutics Appoints Thomas Gidoin As Chief Financial Officer
ReutersAug 20, 2025 4:34 PM
Aug 20 (Reuters) - OSE Immunotherapeutics SA OSE.PA:
OSE IMMUNOTHERAPEUTICS APPOINTS THOMAS GIDOIN AS CHIEF FINANCIAL OFFICER
OSE IMMUNOTHERAPEUTICS SA - THOMAS GIDOIN SUCCEEDS ANNE-LAURE AUTRET-CORNET AS CFO
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
What Is Worldcoin? Why Did WLD Surge Suddenly, and What’s Next?
Worldcoin is evolving from a “hype token” into a foundational layer for global identity. Its fusion of biometrics, blockchain, and financial inclusion has earned growing recognition from users and institutions. If it can overcome technical hurdles, launch real-world payment use cases, and stabilizeTradingKey
Fri, Sep 12
U.S. August CPI Preview: Persistent Rise in Inflation, What Impact on Rate Cuts? And on US Stocks?
TradingKey - On 11 September 2025, the U.S. will publish August CPI data. Consensus forecasts indicate a 0.3% month-over-month increase for both headline CPI and core CPI. As a result, headline CPI year-over-year may climb to 2.9%, up from 2.7%TradingKey
Tue, Sep 9
Fed to Cut Rates: All Asset Prices Up!
TradingKey - The Federal Reserve is almost certain to restart its interest rate cut cycle on 17 September this year. After in-depth research, we have concluded that cryptocurrencies, the broader U.S. stock market, and short-term U.S. Treasury bonds will all go up.TradingKey
Mon, Sep 8
What Is OKB? A Deep Dive into Its Meteoric Rise and Whether the Rally Can Continue
OKB is a deflationary, utility-driven token tightly linked to one of the world’s leading crypto exchanges. Its recent surge is fundamentally supported, not just speculative. If OKX continues to innovate and expand, OKB could remain a high-value asset. But as always, long-term sustainability dependsTradingKey
Fri, Aug 22
.jpg)
Tradingkey
